Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

NCT03593018 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Angioimmunoblastic T-Cell Lymphoma
Refractory Angioimmunoblastic T-cell Lymphoma

Interventions

DRUG: Oral azacitidine
DRUG: Romidepsin
DRUG: Bendamustine
DRUG: Gemcitabine

Sponsor

The Lymphoma Academic Research Organisation

Collaborators

[object Object]